U.S. Bioscience
Executive Summary
Hexalen sales were $ 654,884 from the ovarian cancer treatment's launch on Jan. 22 through March 31, the firm reported May 6. Hexalen (altretamine or hexamethylmelamine) for the palliative treatment of resistant or recurring ovarian cancers following first-line therapy, was approved by FDA on Dec. 26. Chairman and CEO Philip Schein, MD, said that Hexalen "has been stocked by most major wholesalers in the U.S., and subsequently reordered by more than 60% of these accounts".